Newsroom

Sorted by: Latest
-

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi...
-

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

WILMINGTON, Del.--(BUSINESS WIRE)--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET...
-

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® in the United States....
-

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

WILMINGTON, Del.--(BUSINESS WIRE)--Results from Incyte’s frontMIND Trial of Tafasitamab (Monjuvi/Minjuvi) Combination at the 2026 EHA Plenary Showed Prolonged Progression Free Survival...
-

ComEd Continues Power Restoration Following Two Powerful Storms

CHICAGO--(BUSINESS WIRE)--ComEd crews continue restoring power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With the most volatile weather now past the region, crews are focused on completing repairs and restoring service to remaining pockets of customers affected by storm damage. Multiple bands of severe weather brought intense rain, frequent lightning and high wind gusts, causing significant damage to ComEd’s pow...
-

Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings

VANCOUVER, British Columbia--(BUSINESS WIRE)--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (OTCQB: DOCKF) (“Republic” or the "Company") today provided an update with respect to its previously announced management cease trade order ("MCTO") in connection with the Company's filing of its audited annual financial statements (the " Financial Statements") and management discussion and analysis (the "MD&A") for the financial year ended December 31, 2025, and the applicable CEO and CFO certi...
-

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Al...
-

Das grundlegende hämatologische Produktportfolio von BeOne Medicines läutet auf der EHA 2026 eine neue Ära der Innovation bei B-Zell-Krebserkrankungen ein

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, präsentierte heute auf dem Kongress der European Hematology Association (EHA) 2026 in Stockholm neue Daten aus seinem grundlegenden hämatologischen Produktportfolio. Aktualisierte Ergebnisse zu Tacabrutideg (BGB-16673), einem möglichen Best-in-Class-Bruton-Tyrosinkinase (BTK)-Degrader, zeigten anhaltende Ansprechraten bei vorbehandelten Patienten mit rezidiv...
-

IQM nomme Barbara Venneman, membre du conseil d’administration de Vanguard et ancienne directrice mondiale de Deloitte Digital, au sein de son conseil d’administration

ESPOO, Finlande--(BUSINESS WIRE)--IQM Quantum Computers, le leader mondial dans le domaine des ordinateurs quantiques supraconducteurs, a annoncé aujourd’hui la nomination de Barbara Venneman au sein de son conseil d’administration. Mme Venneman va permettre de renforcer l’expertise du conseil d’administration en matière de transformation numérique, de commercialisation de technologies d’entreprise et de développement international, à l’heure où IQM étend sa présence commerciale à l’échelle mon...
-

GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased or acquired WGS common stock between April 16, 2025, and May 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Connecticut and is captioned Taher Basma...